علاج النقائل العظمية في سرطان البروستاتا المقاوم للإخصاء النقيلي مع نقائل هيكلية متعددة عرضية

References

1. 223Ra is a valuable treatment option for patients with mCRPC and symptomatic multiple skeletal metastases as the dominant site of disease.
2. Currently, 223Ra should be given as a single agent [with luteinising hormone-releasing hormone (LHRH) analogues] following previous use and/or in combination with a BTA.
3. A BTA should be started before 223Ra.
4. In the ALSYMPCA trial, patients with symptomatic, bone-dominant disease who failed or were deemed unfit for docetaxel received 223Ra or placebo every 4 weeks in addition to best standard care.
5. The use of this combination is not recommended and, based on these results and experience with combined enzalutamide and 223Ra, a BTA should be started before 223Ra.

DOI: 10.1016/j.annonc.2020.07.019